RxDoctor Payments Data

Mitchell Karl, MD

Cardiovascular Disease · Boca Raton, FLNPI 1932291614

Payments from drug & device makers

$286,359in general payments, 2019–2025

Across 141 payments — averaging $2030.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$279K
  • Akcea Therapeutics, Inc.$3K
  • Cvrx, Inc.$702
  • Atricure, Inc.$612
  • Amgen$591
  • Bayer$338
  • plus $2K from 24 others

What the payments were for

  • Speaking & faculty fees$2,59035%
  • Travel & lodging$5307%
  • Food & beverage$4,24257%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$286,359 in reported general payments places this provider in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$102,278
Medicare patients
118
Services billed
1,135

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban51$81,573
Repatha SureclickEvolocumab28$34,005
OzempicSemaglutide13$13,621
Potassium Chloride29$4,331
Nebivolol Hcl42$1,612
Rosuvastatin Calcium104$1,590
SynthroidLevothyroxine Sodium11$1,281
Metoprolol Succinate52$1,235
Pantoprazole Sodium39$868
Valsartan28$822
Torsemide52$800
Escitalopram Oxalate37$711
Candesartan Cilexetil11$629
Atorvastatin Calcium75$611
Gabapentin25$608

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$325$81,57351 claims
Novo NordiskOzempic$231$13,62113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Boca Raton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →